Clinical Trial Update: A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating combinations of dalotuzumab with MK-2206, MK-0752, or ridaforolimus in advanced cancer; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasms

Drugs mentioned

• Dalotuzumab (dalotuzumab)
• MK-0752
• MK-2206 (MK-2206)
• Ridaforolimus (ridaforolimus)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Neoplasms Malignant | Phase 1 | Status: TERMINATED | Results posted: 2017-10-30